Intrahepatic T helper 17 cells recruited by hepatitis B virus X antigen-activated hepatic stellate cells exacerbate the progression of chronic hepatitis B virus infection.
Th17 cell
hepatic cirrhosis
hepatic stellate cells
hepatitis B virus X antigen (HBxAg)
hepatocellular carcinoma
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
17
12
2019
revised:
18
04
2020
accepted:
18
05
2020
pubmed:
20
6
2020
medline:
26
8
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
Immunopathological injury induced by persistent hepatitis B virus (HBV) infection contributes to the progression from chronic hepatitis B (CHB) to hepatic cirrhosis and hepatocellular carcinoma (HCC). Regulatory T cells (Tregs), CD4
Substances chimiques
Trans-Activators
0
Viral Regulatory and Accessory Proteins
0
hepatitis B virus X protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1138-1149Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Li K, Liu H, Guo T. Th17/Treg imbalance is an indicator of liver cirrhosis process and a risk factor for HCC occurrence in HBV patients. Clin Res Hepatol Gastroenterol. 2017;41(4):399-407.
Oo YH, Weston CJ, Lalor PF, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol. 2010;184(6):2886-2898.
Rau M, Schilling AK, Meertens J, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol. 2016;196(1):97-105.
Azizi G, Hafezi N, Mohammadi H, et al. Abnormality of regulatory T cells in common variable immunodeficiency. Cell Immunol. 2017;315:11-17.
Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204(8):1849-1861.
Brockmann L, Giannou AD, Gagliani N, et al. Regulation of TH17 cells and associated cytokines in wound healing, tissue regeneration, and carcinogenesis. Int J Mol Sci. 2017;18(5):e1033.
Miahipour A, Haji-Fatahaliha M, Keshavarz H, et al. T Helper 1 (Th1), Th2, and Th17 responses to leishmania major lipophosphoglycan 3. Immunol Invest. 2016;45(7):692-702.
Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626-635.
Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.
Weaver CT, Elson CO, Fouser LA, Kolls JK. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol. 2013;8:477-512.
Tosello-Trampont A, Surette FA, Ewald SE, Hahn YS. Immunoregulatory role of NK cells in tissue inflammation and regeneration. Front Immunol. 2017;8:301.
Punt S, Langenhoff JM, Putter H, et al. The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology. 2015;4(2):e984547.
Yousefi M, Movassaghpour AA, Shamsasenjan K, et al. The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia. Future Oncol. 2015;11(10):1567-1582.
Lv D, Jia F, Hou Y, et al. Histone acetyltransferase KAT6A upregulates PI3K/AKT signaling through TRIM24 binding. Cancer Res. 2017;77(22):6190-6201.
Li S, Chen X, Mao L, et al. Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ ERK signaling pathways. Brain Res. 2018;1692:154-162.
Wang B, Zhao CH, Sun G, et al. IL-17 induces the proliferation and migration of glioma cells through the activation of PI3K/Akt1/NF-κB-p65. Cancer Lett. 2019;447:93-104.
Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425-456.
Fujita T, Narumiya S. Roles of hepatic stellate cells in liver inflammation: a new perspective. Inflamm Regen. 2016;25(36):1.
Fujita T, Soontrapa K, Ito Y, et al. Hepatic stellate cells relay inflammation signaling from sinusoids to parenchyma in mouse models of immune-mediated hepatitis. Hepatology. 2016;63(4):1325-1339.
Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol. 2001;36:651-660.
Zhang H, Wu LY, Zhang S, et al. Anti-hepatitis B virus X protein in sera is one of the markers of development of liver cirrhosis and liver cancer mediated by HBV. J Biomed Biotechnol. 2009;2009:289068.
Fabre T, Kared H, Friedman SL, Shoukry NH. IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-β receptor on hepatic stellate cells in a JNK-dependent manner. J Immunol. 2014;193(8):3925-3933.
Wu LY, Liu S, Liu Y, et al. Up-regulation of interleukin-22 mediates liver fibrosis via activating hepatic stellate cells in patients with hepatitis C. Clin Immunol. 2015;158(1):77-87.
Zhang JY, Zhang Z, Lin F, et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology. 2010;51(1):81-91.
Coffelt SB, Kersten K, Doornebal CW, et al. IL-17-producing T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345-348.
Gomes AL, Teijeiro A, Burén S, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2016;30(1):161-175.
You R, DeMayo FJ, Liu J, et al. IL17A regulates tumor latency and metastasis in lung adeno and squamous SQ.2b and AD.1 cancer. Cancer Immunol Res. 2018;6(6):645-657.
Feng D, Kong X, Weng H, et al. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology. 2012;143(1):188-198.e7.
Kurioka A, Walker LJ, Klenerman P, Willberg CB. Erratum: MAIT cells: new guardians of the liver. Clin Transl Immunology. 2017;6(2):e132.
Zhang HB, Luo HC, Xin XJ, Zeng AZ. Up-regulated Reg proteins induced by Interleukin-22 treatment ameliorate acute liver injury in rat model. Int J Clin Exp Med. 2015;8(1):1253-1258.
Kuang DM, Xiao X, Zhao Q, et al. B7-H1-expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets. J Clin Invest. 2014;124(10):4657-4667.
Waidmann O, Kronenberger B, Scheiermann P, et al. Interleukin-22 serum levels are a negative prognostic indicator in patients with hepatocellular carcinoma. Hepatology. 2014;59(3):1207.
Rolla S, Alchera E, Imarisio C, et al. The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice. Clin Sci (Lond). 2016;130(3):193-203.
Zhang Y, Cobleigh MA, Lian JQ, et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology. 2011;141(5):1897-1906.
Zhao J, Zhang Z, Luan Y, et al. Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology. 2014;59(4):1331-1342.
Kong X, Feng D, Wang H, et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology. 2012;56(3):1150-1159.
Pan Q, Yu Y, Tang Z, et al. Increased levels of IL-21 responses are associated with the severity of liver injury in patients with chronic active hepatitis B. J Viral Hepat. 2014;21(9):e78-e88.
Feng G, Zhang JY, Zeng QL, et al. Interleukin-21 mediates hepatitis B virus-associated liver cirrhosis by activating hepatic stellate cells. Hepatol Res. 2014;44(10):E198-E205.
Sun YY, Li XF, Meng XM, et al. Macrophage phenotype in liver injury and repair. Scand J Immunol. 2017;85(3):166-174.
Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4(8):583-594.
Morgado M, Sutton MN, Simmons M, et al. Tumor necrosis factor-alpha and interferon-gamma stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFkappaB. Oncotarget. 2016;7:14871-14884.
Kochupurakkal BS, Wang ZC, Hua T, et al. RelA-induced interferon response negatively regulates proliferation. PLoS One. 2015;10(10):e0140243.
Shime H, Maruyama A, Yoshida S, et al. Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells. Oncoimmunology. 2017;7(1):e1373231.
Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med. 2016;22(3):230-241.
Paquissi FC. Immune imbalances in non-alcoholic fatty liver disease: from general biomarkers and neutrophils to Interleukin-17 axis activation and new therapeutic targets. Front Immunol. 2016;7:490.